T. Rowe Price Associates’s Pacific Biosciences PACB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | $187K | Sell |
|
|||||
|
2025
Q2 | $347K | Buy |
|
|||||
|
2025
Q1 | $308K | Sell |
|
|||||
|
2024
Q4 | $3.24M | Sell |
|
|||||
|
2024
Q3 | $3.13M | Sell |
|
|||||
|
2024
Q2 | $2.66M | Sell |
|
|||||
|
2024
Q1 | $7.33M | Sell |
|
|||||
|
2023
Q4 | $35.3M | Sell |
|
|||||
|
2023
Q3 | $33.3M | Buy |
|
|||||
|
2023
Q2 | $51.7M | Buy |
|
|||||
|
2023
Q1 | $42.2M | Buy |
|
|||||
|
2022
Q4 | $28M | Buy |
|
|||||
|
2022
Q3 | $19.6M | Sell |
|
|||||
|
2022
Q2 | $45.5M | Buy |
|
|||||
|
2022
Q1 | $55.5M | Buy |
|
|||||
|
2021
Q4 | $118M | Buy |
|
|||||
|
2021
Q3 | $145M | Buy |
|
|||||
|
2021
Q2 | $124M | Sell |
|
|||||
|
2021
Q1 | $118M | Buy |
|
|||||
|
2020
Q4 | $86.1M | Buy |
|
|||||
|
2020
Q3 | $23.5M | Buy |
|
|||||
|
2020
Q2 | $293K | Sell |
|
|||||
|
2020
Q1 | $417K | Buy |
|
|||||
|
2019
Q4 | $487K | Buy |
|
|||||
|
2019
Q3 | $460K | Buy |
|
|||||
|
2019
Q2 | $535K | Buy |
|
|||||
|
2019
Q1 | $298K | Buy |
|
|||||
|
2018
Q4 | $302K | Buy |
|
|||||
|
2018
Q3 | $218K | Sell |
|
|||||
|
2018
Q2 | $146K | Buy |
|
|||||
|
2018
Q1 | $84K | Buy |
|
|||||
|
2017
Q4 | $107K | Sell |
|
|||||
|
2017
Q3 | $370K | Hold |
|
|||||
|
2017
Q2 | $251K | Buy |
|
|||||
|
2017
Q1 | $364K | Hold |
|
|||||
|
2016
Q4 | $268K | Hold |
|
|||||
|
2016
Q3 | $632K | Buy |
|
|||||
|
2016
Q2 | $112K | Sell |
|
|||||
|
2016
Q1 | $263K | Hold |
|
|||||
|
2015
Q4 | $406K | Sell |
|
|||||
|
2015
Q3 | $197K | Buy |
|
|||||
|
2015
Q2 | $136K | Hold |
|
|||||
|
2015
Q1 | $138K | Hold |
|
|||||
|
2014
Q4 | $185K | Sell |
|
|||||
|
2014
Q3 | $191K | Hold |
|
|||||
|
2014
Q2 | $240K | Hold |
|
|||||
|
2014
Q1 | $208K | Buy |
|
|||||
|
2013
Q4 | $153K | Sell |
|
|||||
|
2013
Q3 | $349K | Sell |
|
|||||
|
2013
Q2 | $209K | Buy |
|